Comment from Maryland Right to Life, Inc.

Summary: Maryland Right to Life, Inc., a pro-life organization, opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. They argue that the drug poses significant health risks and that robust safety measures are necessary to protect patients from substandard providers and the "abortion industry."